Ph.D., Cellular & Molecular Pharmacology and Physiology
University of Nevada
aging, elderly, Alzheimers, Parkinson's, rapamycin, simvastatin, resveratrol, Aldh1, Gpx1
Aging is the main risk factor for neurodegenerative diseases. Parkinson's disease (PD) is a disorder of the brain that leads to shaking (tremors) and difficulty with walking, movement, and coordination. My studies are focused to test the role of impaired detoxification of biogenic aldehydes and reactive oxygen species in the Gpx1/Aldh1a1 double KO model of Parkinson’s disease and whether the use of aldehyde trapping agents and N-acetylcysteine, separately and/or together will revert the effects, and could provide a new therapeutic approach to intervention in Parkinson ’s disease.
The objectives in these studies are to examine the role of two genes, aldehyde dehydrogenase 1a1 (Aldh1a1) and the glutamate peroxidase 1 (Gpx1), each of whose expression is notably reduced in the nigrostriatal pathway in Parkinson’s disease, and the effects of the aldehyde trapping agent-hydralazine- and or the glutathione precursor N-acetylcysteine in preventing or attenuating the progression of Parkinson’s disease.
Appointments, Boards, Committees and Memberships
Subcommittee for Research Safety - Chairperson South Texas Veterans Health Care System, Research and Development (2010-2011)
Subcommittee for Research Safety - Co-Chairperson South Texas Veterans Health Care System (2009-2010)
Accomplishments, Awards and Honors
Top 10 Stories of 2009 as recognized by Nature - paper on murine life-extension by rapamycin Nature (2009)
The Breakthroughs of 2009 as recognized by Science - paper on murine life-extension by rapamycin Science (2009)